Vigil Neuroscience, Inc. (NASDAQ:VIGL) Director Haeberlein Samantha L. Budd Purchases 12,000 Shares

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) Director Haeberlein Samantha L. Budd bought 12,000 shares of the business's stock in a transaction on Thursday, December 19th. The stock was bought at an average price of $1.71 per share, for a total transaction of $20,520.00. Following the transaction, the director now directly owns 12,000 shares of the company's stock, valued at approximately $20,520. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Vigil Neuroscience Price Performance

Shares of Vigil Neuroscience stock traded up $0.01 during midday trading on Thursday, reaching $1.66. The company had a trading volume of 376,077 shares, compared to its average volume of 240,550. The firm has a market cap of $67.86 million, a PE ratio of -0.81 and a beta of 1.65. The stock has a fifty day moving average price of $3.09 and a 200 day moving average price of $3.51. Vigil Neuroscience, Inc. has a fifty-two week low of $1.60 and a fifty-two week high of $6.06.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on VIGL. HC Wainwright reissued a "buy" rating and set a $17.00 price objective on shares of Vigil Neuroscience in a report on Friday, November 8th. William Blair started coverage on Vigil Neuroscience in a research note on Wednesday, December 4th. They set an "outperform" rating on the stock. Wedbush upped their price objective on Vigil Neuroscience from $23.00 to $24.00 and gave the company an "outperform" rating in a research note on Friday, November 8th. Finally, JMP Securities reiterated a "market outperform" rating and set a $22.00 target price on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Vigil Neuroscience currently has an average rating of "Moderate Buy" and an average target price of $16.60.

Institutional Investors Weigh In On Vigil Neuroscience

A number of institutional investors have recently modified their holdings of the company. Ensign Peak Advisors Inc grew its holdings in Vigil Neuroscience by 72.8% during the 2nd quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company's stock worth $1,580,000 after acquiring an additional 166,442 shares during the period. abrdn plc bought a new stake in Vigil Neuroscience in the third quarter worth approximately $799,000. Point72 Asset Management L.P. bought a new stake in Vigil Neuroscience in the second quarter worth approximately $5,940,000. Verition Fund Management LLC bought a new position in shares of Vigil Neuroscience during the 3rd quarter worth approximately $442,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Vigil Neuroscience during the 2nd quarter worth approximately $87,000. 83.64% of the stock is owned by institutional investors.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.